### 100 Days of Results: President Trump’s American Patients First Blueprint

#### Lower Out-of-Pocket Costs
- Put industry on notice that “gag clauses” causing seniors to pay more at the pharmacy are unacceptable
- Supported passage out of committee of legislation to ban private-sector gag clauses
- Proposed to decrease the price paid by taxpayers and patients for certain new drugs in Medicare
- Clarified tools that Part D plans have to help patients access low-cost generics rather than more expensive, branded competitors
- Proposed lower payments for certain discounted drugs, meaning lower out-of-pocket costs for seniors at more sites of care
- Announced that the average Part D premium would drop for the second year in a row

#### Increased Competition
- Approved, through FDA, a record number of generic drugs in July
- Approved first product designated as a “competitive generic therapy” under a pathway created to expedite development and review of products that lack competition
- Launched a working group on how safe, short-term importation of certain medically necessary drugs could address price spikes
- Announced an FDA Biosimilar Action Plan to spur competition among expensive biologic drugs
- Took action to stop drug companies from gaming certain FDA safety programs to block cheaper competition

#### Better Negotiation
- Gave Medicare Advantage new negotiation tools to drive down prices for patients
- Provided new guidance to help insurers and drug companies reach better deals for patients
- Solicited comment on ways to use private-sector competitive acquisition for Medicare Part B drugs
- Approved first-of-its-kind waiver for a state to negotiate pricing contracts with drug makers to secure more value

#### Incentives for Lower List Prices
- Supporting the introduction of legislation to undo the Obamacare giveaway to drug companies on Medicaid rebates
- Began publishing individual drug price increases on CMS’s drug dashboard
- Worked with drug companies to secure historically unprecedented rollbacks or cuts in list prices

---

“The President’s blueprint for lower drug prices is working, drug prices are coming down, and American patients are going to see the savings in their pocketbook.”

— Secretary Alex Azar
## 100 Days of Results: President Trump’s American Patients First Blueprint

### Drug company responses:

<table>
<thead>
<tr>
<th>Action</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lowering Prices or Rolled Back Increases</td>
<td>2</td>
</tr>
<tr>
<td>Committed to Price Freezes for Rest of 2018</td>
<td>13</td>
</tr>
<tr>
<td>Canceled Planned Price Increases</td>
<td>4</td>
</tr>
</tbody>
</table>

### Since the blueprint release, drug companies have implemented:

- **60%** fewer brand-drug price increases than the same period in 2017
- **54%** more generic and brand-drug price decreases than the same period in 2017

### Other highlights:

- **20 million** Seniors on Medicare Advantage plans that will now have new tools to negotiate
- **Record-Breaking 126 generics** Approved in July
- **3,028** Comments on the Blueprint